Particle.news
Download on the App Store
6 ARTICLES
·
last wk.

Zimmer Biomet Cuts Organic Growth Outlook to 4% Upper Range as Shares Fall on Q3 Update

Late-quarter softness across Latin America plus emerging European markets offset strong U.S. demand, prompting the guidance change.

The logo of medical implants maker Zimmer Biomet is seen at a plant in Winterthur, Switzerland, January 23, 2017. Picture taken on January 23, 2017. REUTERS/Arnd Wiegmann
Image
Image

Overview

  • The company narrowed 2025 organic revenue guidance to 3.5%–4.0% and kept full-year reported sales and adjusted EPS targets intact.
  • Q3 net sales were about $2.0 billion and adjusted EPS was $1.90, topping consensus.
  • U.S. organic revenue grew 5.6% on accelerated adoption of new products referred to as the “Magnificent Seven.”
  • Hips and knees generated $1.30 billion, slightly above expectations, while sports medicine, extremities and trauma rose 19% to $541.5 million but missed estimates.
  • Management raised its expected FX tailwind to 0.5%–1.0% and the stock fell sharply in early trading following the update.